A Phase 3 Open-label Trial To Assess The Safety, Tolerability, And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Infants And Young Children In China Who Are Naive To Pneumococcal Vaccination
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 11 Jul 2018 Planned End Date changed from 23 Aug 2023 to 24 Aug 2023.
- 11 Jul 2018 Planned primary completion date changed from 15 Aug 2019 to 16 Aug 2019.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting.